
|Articles|April 2, 2007
Latebreakers: Breast cancer agent gets green light
Patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed following treatment with an anthracycline, a taxane, and trastuzumab (Herceptin, Genentech) will now have a new therapeutic option. Lapatinib (Tykerb, GlaxoSmithKline) has been approved by the FDA for use in combination with capecitabine (Xeloda, Roche) following a priority review.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5







































